For the quarter ending 2026-03-31, EWTX has $518,522K in assets. $25,319K in debts. $33,211K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 33,211 | 61,148 | 46,003 | 43,404 |
| Marketable securities, available for sale | 466,351 | 468,961 | 517,337 | 550,588 |
| Prepaid expenses and other assets | 10,230 | 13,276 | 10,560 | 9,263 |
| Total current assets | 509,792 | 543,385 | 573,900 | 603,255 |
| Property and equipment, net | 7,396 | 7,831 | 8,129 | 8,595 |
| Operating lease right-of-use asset | 1,334 | 1,387 | 1,437 | 1,484 |
| Total assets | 518,522 | 552,603 | 583,466 | 613,334 |
| Accounts payable | 7,293 | 6,006 | 6,157 | 8,320 |
| Accrued compensation | 5,678 | 12,430 | 7,998 | 5,636 |
| Accrued other expenses | 8,555 | 7,920 | 6,483 | 5,936 |
| Operating lease liability, current portion | 1,017 | 1,014 | 1,008 | 1,004 |
| Total current liabilities | 22,543 | 27,370 | 21,646 | 20,896 |
| Operating lease liability, net of current portion | 2,776 | 2,976 | 3,173 | 3,367 |
| Preferred stock, .0001 par value per share 200,000,000 shares authorized and no shares issued or outstanding as of june 30, 2025 and december 31, 2024 | - | - | - | 0 |
| Total liabilities | 25,319 | 30,346 | 24,819 | 24,263 |
| Common stock, .0001 par value per share 1,000,000,000 shares authorized as of march 31, 2026 and december 31, 2025 107,481,522 shares and 106,249,579 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 10 | 10 | 10 | 10 |
| Additional paid-in capital | 1,088,829 | 1,067,941 | 1,054,091 | 1,044,346 |
| Accumulated other comprehensive income (loss) | -252 | 677 | 701 | 204 |
| Accumulated deficit | -595,384 | -546,371 | -496,155 | -455,489 |
| Total stockholders' equity | 493,203 | 522,257 | 558,647 | 589,071 |
| Total liabilities and stockholders' equity | 518,522 | 552,603 | 583,466 | 613,334 |
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX)